Avanir Pharmaceuticals, Inc. Avanir Pharmaceuticals, Inc., et al. v. Actavis South Atlantic LLC, et al. (D. Del 2011) – Nuedexta® Avanir Pharmaceuticals, Inc., et al. v. Par Pharmaceutical, Inc., et al. (D. Del 2011) – Nuedexta® Avanir Pharmaceuticals, Inc., et al. v. Wockhart, Ltd., et al. (D. Del 2011) – Nuedexta® Avanir Pharmaceuticals, Inc., et al. v. Impax Laboratories, Inc. (D. Del 2011) – Nuedexta® Bristol-Myers Squibb Company Zenith Labs. v. Bristol-Myers Squibb Co. (D.N.J.) (Fed. Cir. 1992) - Duracef® Bristol-Myers Squibb Co. v. Danbury Pharmaceutical (S.D.N.Y. 1991) - Buspar® Celgene Corporation Celgene Corp. v. Barr Laboratories, Inc., et al., (D.N.J. 2007) - Thalomid® Celgene Corp. v. Natco Pharma Ltd., et al., (D.N.J. 2010) - Revlimid® Esperion Therapeutics, Inc. Talaria Theraputics, Inc. v. Esperion Theraputics, Inc. et al. (E.D. Va. 2001) - cholesterol reducing agents Jazz Pharmaceuticals, Inc. Jazz Pharmaceuticals, Inc. v. Roxane Laboratories, Inc. (D.N.J. 2010) - Xyrem® King Pharmaceuticals, Inc./King Pharmaceuticals Research & Development, Inc. King Pharmaceuticals, Inc. v. Sandoz Inc. (D.N.J. 2009) - Avinza® King Pharmaceuticals Research & Development, Inc. v. Item Development AB, Interference No. 105,620 (2008) - Adenoscan®
quinn emanuel urquhart & sullivan, llp
Los Angeles • New York • San Francisco • Silicon Valley • Chicago • Washington, D.C. • Tokyo • London • Mannheim • Moscow • Hamburg
Prior results do not guarantee a similar outcome.
King Pharmaceuticals Research & Development, Inc. v. Anazao Health Corp. et al. (C.D. Cal. 2008) - Adenoscan® King Pharmaceuticals, Inc. et al. v. Sandoz, Inc. (D.N.J. 2008) - Skelaxin® King Pharmaceuticals, Inc. et al. v. Actavis, Inc. et al. (D.N.J. 2007) - Avinza® King Pharmaceuticals and Astellas US LLC v. Sicor Inc. and Teva Pharmaceuticals USA, Inc. (D.Del. 2005) - Adenoscan® King Pharmaceuticals, Inc. and Wyeth v. Teva Pharmaceuticals USA, Inc. (D.N.J. 2005) - Sonata® Aventis Pharma Deutschland GmbH and King Pharmaceuticals v. Lupin Pharmaceuticals USA, Inc. (D. Md. 2005) - Altace® King Pharmaceuticals, Inc. v. Eon Labs, Inc. (E.D.N.Y. 2005) - Skelaxin® King Pharmaceuticals, Inc. v. Mutual Pharmaceuticals Co., Inc. (E.D. Pa. 2004) - Skelaxin® King Pharmaceuticals, Inc. v. Barr Laboratories (S.D.N.Y. 2004) - Prefest® Classen Immunotherapies v. King Pharmaceuticals, Inc. (D. Md. 2004) - Skelaxin® King Pharmaceuticals, Inc. v. Biotech Pharmacy, Inc. (D. Nev. 2004) - Adenoscan® King Pharmaceuticals, Inc. v. CorePharma, LLC (E.D.N.Y. 2003) - Skelaxin® King Pharmaceuticals, Inc. v. Eon Labs, Inc. (E.D.N.Y. 2003) - Skelaxin® King Pharmaceuticals, Inc. v. Mylan Labs (N.D. W.Va. 2003) - Levoxyl® King Pharmaceuticals, Inc. v. KV Pharmaceuticals (D. Del. 2003) - Levoxyl® King Pharmaceuticals and Aventis Deutschland GmbH v. Cobalt Pharmaceuticals (D. Mass. 2002) - Altace® Kremers Urban Development Company, Schwarz Pharma, Inc. In re Omeprazole Litigation, MDL Docket No. 1291 (M-21-81) (S.D.N.Y. 1999) - Prilosec® aaiPharma Inc. v. KudCo et al. (S.D.N.Y. 2002) - Prilosec® LeaRonal, Inc. Ishihara Chemical v. LeaRonal, Inc. (E.D.N.Y 1998.) (2d Cir. in related case) - industrial chemicals Lubrizol Corporation Exxon Co. v. Lubrizol Corp. (S.D.Tex.) (Fed. Cir. 1997) - industrial chemicals Marion Merrell Dow/Tanabe Seiyaku Co. Marion Merrell Dow v. Hoechst-Roussel (D.N.J. 1994) - Cardizem® Marion Merrell Dow v. Par Pharmaceuticals (S.D.N.Y. 1995) - Seldane® Tanabe Seiyaku Co. and Marion Merrell Dow v. Mylan Pharmaceuticals et al. (ITC.) (Fed. Cir. 1993) - Cardizem® Tanabe Seiyaku Co. and Marion Merrell Dow v. Fermion Pharmaceuticals (ITC 1992) - Cardizem® Tanabe Seiyaku Co. and Marion Merrell Dow v. Profarmaco (ITC 1992) - Cardizem® Tanabe Seiyaku Co. and Marion Merrell Dow v. ABIC Pharmaceuticals (ITC 1992) - Cardizem® Marion Merrell Dow v. Geneva Pharmaceuticals (D.Col.) - Seldane® Merz Pharmaceutials GmbH & Co. Forest Laboratories and Merz Pharma GmbH & Co. v. Cobalt Laboratories, Inc. (D. Del. 2008) - Namenda® Forest Laboratories and Merz Pharma GmbH & Co. v. Lupin Pharmaceuticals, Inc. (D. Del. 2008) - Namenda® Forest Laboratories and Merz Pharma GmbH & Co. v. Orchid Chemicals & Pharmaceuticals, Inc. (D. Del. 2008) - Namenda® Forest Laboratories and Merz Pharma GmbH & Co. v. Teva Pharmaceuticals, Inc. (D. Del. 2008) - Namenda® Forest Laboratories and Merz Pharma GmbH & Co. v. Upsher-Smith Laboratories, Inc. (D. Del. 2008) - Namenda® Forest Laboratories and Merz Pharma GmbH & Co. v. Wochardt USA Inc. (D. Del. 2008) - Namenda® Forest Laboratories and Merz Pharma GmbH & Co. v. PLIVA (D. Del. 2008) - Namenda® Forest Laboratories and Merz Pharma GmbH & Co. v. Dr. Reddy’s Laboratories, Inc. (D. Del. 2008) - Namenda® Forest Laboratories and Merz Pharma GmbH & Co. v. Genpharm Inc. (D. Del. 2008) - Namenda® Forest Laboratories and Merz Pharma GmbH & Co. v. Interpharm Holdings, Inc. (D. Del. 2008) - Namenda® Forest Laboratories and Merz Pharma GmbH & Co. v. Mylan Pharmaceuticals, Inc. (D. Del. 2008) - Namenda® Forest Laboratories and Merz Pharma GmbH & Co. v. Sun India Pharmaceutical Industries Limited (D. Del. 2008) - Namenda® Forest Laboratories and Merz Pharma GmbH & Co. v. Ranbaxy Inc. (D. Del. 2008) - Namenda® Forest Laboratories and Merz Pharma GmbH & Co. v. Synthon Laboratories, Inc. (D. Del. 2008) - Namenda® Forest Laboratories and Merz Pharma GmbH & Co. v. Orgenus Pharma Inc. (D. Del. 2008) - Namenda® Forest Laboratories and Merz Pharma GmbH & Co. v. Apotex Inc. (D. Del. 2008) - Namenda® Prometheus Laboratories, Inc. Prometheus Laboratories, Inc. v. Roxane Laboratories, Inc. (D.N.J 2011) - Lotronex® Purdue Pharma L.P. Purdue Pharma L.P. v. Faulding Pharmaceuticals (D. Del. 1999) – MS Contin® Purdue Pharma L.P. v. Teva Pharmaceuticals Indus. Ltd. (S.D.N.Y. 2001) - Oxycontin® Schwarz Pharma, Inc. Schwarz Pharma, Inc. and Elan Corporation v. Mylan Pharmaceuticals, Inc. (N.D. W.Va. 2006) - Verelan® Schwarz Pharma, Inc. v. Paddock Laboratories, Inc. (D. Minn. 2005) - Univasc® Schwarz Pharma, Inc. and Cima Labs, Inc. v. Par Pharmaceutical Companies, Inc., et al., (D.N.J. 2006) - Niravam TM Schwarz Pharma, Inc. and CIMA Labs, Inc. v. Actavis Group hf., et al., (D.N.J. 2007) - Niravam™ Schwarz Pharma Inc. v. Teva Pharmaceuticals (D.N.J. 2004) - Uniretic® In re: Omeprazole (S.D.N.Y.) (Fed. Cir. 2003) - Prilosec®
Braintree Laboratories v. Schwarz Pharma, Inc. (D. Del. 2003) - Miralax® Schwarz Pharma, Inc. v. Teva Pharmaceuticals (D.N.J. 2001) - Univasc® Tanabe Seiyaku Tanabe Seiyaku Co. v. United States International Trade Commission (Fed. Cir. 1997) - Cardizem® Development Agreements $100 million development agreement with Cobalt Labs for the development of a tablet formulation for Altace® (2006) $200 million development agreement with Pain Therapeutics regarding Remoxy®, a tamper- resistant opoid product (2005) $50 million strategic alliance with Palatin Technologies, Inc. to develop and market PT-141 for sexual dysfunction (2004) Product Acquisitions $800 million acquisition of Sonata® and Skelaxin® from Elan PLC (2003)
BANK OF MAURITIUS ANNUAL DINNER WITH ECONOMIC STAKEHOLDERS Address by Mr. R. Basant Roi, Governor of the Bank of Mauritius on 30 November 2001 I welcome you all to the Bank of Mauritius Annual Dinner. I am delighted to address you once again on this occasion. Three years ago, on this same occasion, I had emphasised the importance of good corporate governance as a basis for best busine
Lose 10 Pounds and Your Blood Pressure Medication Date updated: September 27, 2006 By Darin Painter Content provided by Revolution Health Group http://www.revolutionhealth.com/conditions/heart/high-blood-pressure/treat- overview/blood-pressure-medication Toprol, Inderal, Blocadren, Levatol — it's hard enough tough to pronounce these blood pressure medicines, let alone take them daily
